Chronic inflammatory demyelinating polyneuropathy (CIDP) is considered to be an autoimmune disorder of the peripheral nervous system. Central nervous system (CNS) involvement has been clinically observed in 5% and 8%of patients and in many
cases of CIDP, there is accompanying CNS demyelination with the presence of subclinical electrophysiological and magnetic resonance imaging (MRI) abnormalities. CIDP is an acquired, immune-mediated disease that targets the myelin sheaths of peripheral nerves. CIDP involves both demyelination and axonal degeneration, with the balance being determined by disease duration and severity. The measurement of VEPs was a useful technique for the diagnosis of visual pathway involvement, but was of no value for monitoring the effect of treatment in CIDP patients. We concur with this finding, as CIDP patients with prolonged P100 latency in the present study had shorter VEP latency in both eyes after treatment with IVIg. Moreover, the VEP parameters in patients with CIDP showed overall improvement with IVIg therapy, further supporting that its administration may be effective even for CNS lesions in CIDP.
Last date updated on July, 2021